Study of Vitamin C, Vitamin E and Their Combination to Treat Restless Legs Syndrome in Hemodialysis Patients
Launched by SHIRAZ UNIVERSITY OF MEDICAL SCIENCES · May 17, 2010
Trial Information
Current as of June 07, 2025
Completed
Keywords
ClinConnect Summary
RLS is a common problem in hemodialysis patients; 20 to 40% of hemodialysis patients suffer from RLS. Hemodialysis patients have a high oxidative stress status. Oxidative stress has been proposed to play an important role in the pathogenesis of RLS. Vitamin C and vitamin E are potent antioxidant agents that have already been shown to be effective in the treatment of periodic limb movement disorder (PLMD) in hemodialysis patients. PLMD is closely associated with RLS in hemodialysis patients. The aim of this study was to evaluate the efficacy of vitamin C, vitamin E and their combination in t...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who fulfill Restless leg syndrome international criteria(IRLSSG)
- • Patients who are stable on HD without any internment illness or admission
- Exclusion Criteria:
- • Patients who have renal stone
- • Patients who receive medications with RLS aggravating or alleviating properties
About Shiraz University Of Medical Sciences
Shiraz University of Medical Sciences (SUMS) is a leading academic institution in Iran dedicated to advancing healthcare through innovative research and education. As a prominent clinical trial sponsor, SUMS plays a pivotal role in conducting rigorous clinical studies aimed at improving medical practices and patient outcomes. The university is committed to fostering collaboration among healthcare professionals, researchers, and industry partners to translate scientific discoveries into effective therapies. With a focus on ethical standards and regulatory compliance, SUMS strives to contribute to the global body of medical knowledge while enhancing the quality of care within the community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shiraz, Fars, Iran, Islamic Republic Of
Patients applied
Trial Officials
Hamideh Akbari, MD
Principal Investigator
Shiraz University of Medical Sciences
Mohammad Mahdi Sagheb, MD
Study Chair
Shiraz University of Medical Sciences
Sahar Sohrabi Nazari, MD
Principal Investigator
Shiraz University of Medical Sciences
Mohammad Kazem Fallahzadeh, MD
Principal Investigator
Shiraz University of Medical Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials